Greenwich LifeSciences (NASDAQ:GLSI) shares surged around 54% after the company said the U.S. Food and Drug Administration ...

Shares of Greenwich LifeSciences climbed after the company said the Food and Drug Administration approved the use of commercially manufactured GP2 in a Phase III trial of its therapy to prevent breast ...

The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for cholesterol-lowering drug Nexlizet. | The FDA is apparently not charmed by the ...

In question is Esperion’s Lipid Lurkers educational campaign, which was launched in July 2024 with support from agency partner GSW, powered by Syneos Health.

Greenwich LifeSciences (GLSI) stock jumps after the FDA okays the first commercial GP2 lot for its Phase 3 FLAMINGO-01 breast cancer trial. Read more here.

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the Food and Drug ...

In the first Untitled Letter issued by the FDA in 2026, BeOne Medicines was critiqued for a DTC TV ad promoting its BTK ...

Investing.com -- Greenwich LifeSciences (NASDAQ:GLSI) stock surged 54% after the company announced that the U.S. Food and Drug Administration (FDA) has approved the use of its first commercially ...

Bridge to Life has received FDA De Novo clearance for its VitaSmart hypothermic oxygenated perfusion (HOPE) system for liver ...

Company Transitions from Infrastructure Buildout to Active Market Execution as Expanded 510(k) Review Enters Final ...